Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

  • Letter
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Longitudinal assessment of HBV-DNA, liver function, serum immunoglobulin, B-cell recovery, and overall survival (OS) of HBsAg-positive DLBCL patients who underwent CD19-CAR-T cell therapy.

References

  1. Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J. 2010;40:633–41.

    Article  CAS  Google Scholar 

  2. Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131:2670–81.

    Article  CAS  Google Scholar 

  3. Wang C, Xia B, Ning Q, Zhao H, Yang H, Zhao Z, et al. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China. Ann Hematol. 2018;97:453–7.

    Article  Google Scholar 

  4. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab- chemotherapy: a meta-analysis. J Clin Virol. 2013;57:209–14.

    Article  CAS  Google Scholar 

  5. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.

    Article  CAS  Google Scholar 

  6. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

    Article  CAS  Google Scholar 

  7. Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131:121–30.

    Article  CAS  Google Scholar 

  8. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–2.

    Article  CAS  Google Scholar 

  9. Downs LO, Smith DA, Lumley SF, Patel M, McNaughton AL, Mokaya J, et al. Electronic Health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection. MBio. 2019;10:e00699–19.

    Article  CAS  Google Scholar 

  10. Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104:435–43.

    Article  CAS  Google Scholar 

  11. Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7:2344–51.

    Article  Google Scholar 

  12. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54.

    Article  CAS  Google Scholar 

  13. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.

    Article  CAS  Google Scholar 

  14. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30.

    Article  CAS  Google Scholar 

  15. Al-Mansour MM, Alghamdi SA, Alsubaie MA, Alesa AA, Khan MA. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. Infect Agent Cancer. 2018;13:18.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by funds from the National Natural Science Foundation of China (No. 81830006, 81830004, 81670178), Science Technology Department of Zhejiang Province (No. 2018C03016-1), and the Natural Science Foundation of Zhejiang Province (No. LY20H080006, LY18H16008).

Author information

Author notes

  1. These authors contributed equally: Chunmei Yang, Mixue Xie

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China

    Chunmei Yang & Mixue Xie

  2. Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China

    Chunmei Yang, Mixue Xie, Kaifeng Zhang & Wenbin Qian

  3. Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China

    Hui Liu & Wenbin Qian

  4. Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China

    Aibin Liang

  5. Hematopathology Division and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, Durham, NC, 27710, USA

    Ken H. Young

Authors
  1. Chunmei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mixue Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaifeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aibin Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken H. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenbin Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception, design, and manuscript writing: WQ, AL, and KHY. Collection, analysis, and interpretation: CY, MX, KZ, and HL. All authors were involved at each stage of manuscript preparation and approved the final version.

Corresponding authors

Correspondence to Aibin Liang, Ken H. Young or Wenbin Qian.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, C., Xie, M., Zhang, K. et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia 34, 3055–3059 (2020). https://doi.org/10.1038/s41375-020-0913-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0913-y

  • Springer Nature Limited

This article is cited by

Search

Navigation